Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

New chronic lymphocytic leukaemia therapies: Does measurable residual disease testing accurately predict progression-free survival

View Full Paper
Ask AI
Bookmark
Share

Authors

YWYun WangCLChun-Hua LiRGRobert Gale

Discussion

Loading...

Member takes

Overview

Analysis shows reduced predictive accuracy of MRD testing for progression-free survival in chronic lymphocytic leukaemia, indicating limitations in BTKi therapy.

Key Points

  • Detection of measurable residual disease significantly influences progression-free survival among chronic lymphocytic leukaemia patients.
  • Sensitivity analysis revealed that MRD testing may not accurately predict progression-free survival, particularly in patients receiving BTKi therapies.
  • Incorporating various therapeutic approaches, including venetoclax and chemoimmunotherapy, highlights the complexity of treatment outcomes.
  • Bone marrow MRD testing proved superior in predicting deterioration compared to blood sampling in the context of clinical trials.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dce6https://doi.org/10.1182/blood-2025-2132
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Minimal residual disease as a prognostic marker in chronic lymphocytic leukemia: A meta-analysis across chemoimmunotherapy and targeted therapies2025
  2. 2Measurable residual disease in newly diagnosed multiple myeloma: Experience from a large cohort from an academic medical center2025
  3. 3What remains matters: Real-world impact of measurable residual disease testing in multiple myeloma2025
  4. 4ClonoSEQ MRD negativity at day 90 is a strong predictor for progression-free and overall survival after BCMA-directed CAR T-cell therapy for relapsed multiple myeloma.2025
  5. 5Circulating tumor DNA-based minimal residual disease assessment predicts progression-free survival in diffuse large B-cell lymphoma: A systematic review and meta-analysis2025 · 1 citations